Search

everythinglearnresearchcommunity

for

Search:↓

A user is interested in Absci's AI-driven antibody platform, ABS-201, for treating androgenetic alopecia, which shows promising preclinical results and potential for hair regrowth and pigmentation restoration. However, concerns are raised about the drug's development timeline and its advantages compared to existing treatments.

Combining therapies like scyllo-inositol, alpha-ketoglutarate, and autophagy-inducing supplements may enhance hair growth and prevent hair loss. Reporting individual results can accelerate progress in hair loss treatments.

Researching the release of phase 2 trials for pyrilutamide, a potential hair loss treatment, and discussing other treatments such as Minoxidil, Finasteride, and RU58841.

A user reported significant hair improvement using oral minoxidil, Rogaine 5%, and spironolactone but experienced worsening PMS. They seek advice on managing the PMS symptoms.

PTD-DBM is being explored for hair regrowth by targeting CXXC5, with clinical trials expected after pre-clinical studies. Users express anticipation and skepticism about its effectiveness.

A Phase 1 update for the HMI 115 clinical trial, which involves 16 participants and is expected to end in July 2023; as well as changes to the recruitment process, including treatment protocols with Minoxidil, Finasteride, and RU58841.

The conversation discusses the tension theory of baldness, suggesting that over-developed masseter muscles may harm hair follicles. Botox injections to relax these muscles reportedly led to an 18% increase in hair count in men with AGA.

Minoxidil can cause scalp itchiness, often due to propylene glycol, and users suggest alternatives like foam formulations without PG, using moisturizing oils, or reducing application frequency. Some recommend ketoconazole or zinc pyrithione shampoos to help with inflammation and itchiness.

Pyrilutamide is a selective AR antagonist with a high binding affinity, making it effective in competing with DHT for androgen receptors. The 1% concentration is more effective than the 0.5%, but the latter may suffice for mild hair loss; the drug is considered a good option for those avoiding 5AR blockers due to side effects.

The conversation is about the lack of improvement in hair loss after using Pyrilutamide for 14 weeks, with the original poster unable to use Finasteride due to depression. Replies suggest that Pyrilutamide, like RU58841, may not work for everyone, and a more potent drug is being developed by Kintor.

User experienced itching, redness, and hives from Minoxidil foam and is questioning if they are allergic to Minoxidil or another ingredient. They have switched to oral Finasteride.

PP405 is a new hair loss treatment advancing quickly in trials, generating excitement and skepticism about its effectiveness and marketing claims. Some see it as a potential alternative to minoxidil and finasteride, but concerns about long-term effects and the need for DHT blockers persist.

Hair loss itch stopped by adding RU58841 to treatment. Topical Finasteride and Pyrilutamide also mentioned as potential itch solutions.

PP405 shows initial promise for treating androgenetic alopecia, with safety confirmed in early trials, but skepticism remains due to limited data. Further trials are needed to determine its true efficacy and potential market impact.

Kintor plans to release pyrilutamide foam and a plant-based Koshine by year-end, with GT20029 progressing in their pipeline. Users are pleased about the absence of propylene glycol (PG) in the new products.

Hair growth can be induced without stopping DHT, as seen with Minoxidil. HMI115 may work by promoting follicle growth, not targeting the root cause of hair loss (DHT).

Corticosterone inhibits GAS6, affecting hair follicle stem-cell activity, with potential implications for stress-related hair loss. Ashwagandha and Vitamin K are suggested for reducing cortisol, but their effectiveness is debated.

The user experienced increased hair shedding after using RU58841 for two months, but found relief from scalp itchiness. Other users shared similar shedding experiences and discussed side effects like joint pain, while also mentioning the use of finasteride and minoxidil.

A 30-year-old man experienced significant hair loss after starting testosterone replacement therapy (TRT), which did not improve with daily finasteride and minoxidil. He is considering restarting TRT and is seeking advice on using pyrilutamide or RU58841 to prevent further hair loss.

The user is experiencing hairline thinning despite using finasteride, minoxidil (solution and foam), dermastamping, and tretinoin. They suspect minoxidil or tretinoin might be causing the issue but are unsure.

The user is experiencing progressive hair thinning despite using finasteride and dutasteride. A biopsy confirmed male pattern baldness, and minoxidil was suggested as an additional treatment.

Hair loss treatments discussed include Minoxidil, Finasteride, and RU58841. Anageninc stopped selling KX-826 (Pyrilutamide) due to a cease and desist letter from Kintor, but this may indicate promising study results and a potential 2024 release.

Minoxidil may cause wrinkles and dark circles, which some users report can be mitigated by adjusting dosage. Reactions vary, and while some dismiss these side effects, others experience significant changes.

The user is seeking alternatives to propylene glycol and glycerin for mixing with RU58841 due to allergies and greasiness. Suggestions include reducing glycerin and considering stemoxydine as a solvent.

A 31-year-old experiencing rapid hair loss is considering whether to shave their head or use treatments. They were prescribed B12, topical finasteride 0.1%, and minoxidil 10% but are unsure about the correct dosage and potential side effects.

The user is experiencing chest sensitivity and muscle ache after using topical finasteride for a month and is concerned about potential gynecomastia. They are considering asking their doctor for blood work to check estrogen levels and are questioning whether to stop using finasteride.

PP405 is progressing rapidly through trials, with mixed opinions on its potential effectiveness. Current treatments like minoxidil and finasteride are still widely discussed, with some users reporting positive results from new formulations.

A user shared their personal theory on hair loss, suggesting it's caused by reduced blood flow and scalp calcification rather than DHT, and claimed to have stopped their hair loss by massaging the scalp, using acid peels, and applying oils and copper peptides. They have not noticed further hair loss for six years since starting this routine.

A 28 year old using a hair loss prevention protocol to restore thinning hair, which includes finasteride, dutasteride, minoxidil, stemoxydine, alopecin, nizoral shampoo and microneedling; the user is now adding pyrilutamide solution to the regimen with the hope of improving their results. RU58841 was also ordered but not yet used.

PTD-DBM therapy for hair loss is being developed by Dr. Kang-Yell Choi, with human testing planned in South Korea. Some clinics in the U.S. offer PTD-DBM/valproic acid therapy, but it hasn't completed trials yet.